Samsara BioCapital’s Aclaris Therapeutics ACRS Stock Holding History

Samsara BioCapital’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,385,060	Closed	-$5.91M	–	38
2024 Q4	$5.91M	Buy	2,385,060 +1,688,889	+243%	+$4.2M	0.81%	21
2024 Q3	$801K	Hold	696,171	–	–	0.15%	34
2024 Q2	$766K	Hold	696,171	–	–	0.16%	34
2024 Q1	$863K	Hold	696,171	–	–	0.13%	33
2023 Q4	$731K	Hold	696,171	–	–	0.11%	33
2023 Q3	$4.77M	Hold	696,171	–	–	1.46%	19
2023 Q2	$7.22M	Hold	696,171	–	–	1.27%	15
2023 Q1	$5.63M	Hold	696,171	–	–	1.16%	20
2022 Q4	$11M	Hold	696,171	–	–	2.36%	11
2022 Q3	$11M	Hold	696,171	–	–	2.56%	8
2022 Q2	$9.72M	Sell	696,171 -98,000	-12%	-$1.37M	2.59%	8
2022 Q1	$13.7M	Hold	794,171	–	–	3.45%	10
2021 Q4	$11.5M	Hold	794,171	–	–	2.24%	11
2021 Q3	$14.3M	Hold	794,171	–	–	2.24%	14
2021 Q2	$13.9M	Sell	794,171 -228,441	-22%	-$5.19M	1.72%	13
2021 Q1	$25.8M	Sell	1,022,612 -340,000	-25%	-$6.65M	4.75%	7
2020 Q4	$8.82K	Sell	1,362,612 -790,653	-37%	-$3.34M	0.89%	12
2020 Q3	$5.53M	Sell	2,153,265 -454,852	-17%	-$1.02M	1.54%	16
2020 Q2	$4.22M	Hold	2,608,117	–	–	1.36%	19
2020 Q1	$2.71M	Buy	+2,608,117	New	+$3.55M	1.56%	18

Other funds holding ACRS

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Samsara BioCapital's ACRS Position: Q1 2025 in Review

Samsara BioCapital sold out of Aclaris Therapeutics (ACRS) in Q1 2025, closing a stake of 2,385,060 shares — an estimated $5.91M sold.

Samsara BioCapital first reported a position in ACRS in Q1 2020 and held it in 20 quarters. The position peaked at $25.8M in Q1 2021. 109 funds tracked by Wall St. Rank hold ACRS as of Q1 2025.

Samsara BioCapital reported no remaining Aclaris Therapeutics position as of Q1 2025 after selling out during the quarter.
Samsara BioCapital sold 2,385,060 Aclaris Therapeutics shares in Q1 2025, an estimated $5.91M.
Samsara BioCapital first reported a position in Aclaris Therapeutics in Q1 2020 and held it in 20 quarters.
Samsara BioCapital's Aclaris Therapeutics position peaked at $25.8M in Q1 2021.
109 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2025.

Based on Samsara BioCapital's 13F filing for Q1 2025, filed 15 May 2025.